Blurbs

RBC Capital Reaffirms Their Hold Rating on Crispr Therapeutics AG (CRSP)

In a report released today, Luca Issi from RBC Capital maintained a Hold rating on Crispr Therapeutics AG (CRSPResearch Report), with a price target of $79.00. The company’s shares closed yesterday at $81.39.

Issi covers the Healthcare sector, focusing on stocks such as Bluebird Bio, Crispr Therapeutics AG, and Caribou Biosciences. According to TipRanks, Issi has an average return of -10.2% and a 39.19% success rate on recommended stocks.

In addition to RBC Capital, Crispr Therapeutics AG also received a Hold from Barclays’s Gena Wang in a report issued today. However, on the same day, JMP Securities maintained a Buy rating on Crispr Therapeutics AG (NASDAQ: CRSP).

See Insiders’ Hot Stocks on TipRanks >>

Based on Crispr Therapeutics AG’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $178 thousand and a GAAP net loss of $179.22 million. In comparison, last year the company earned revenue of $202 thousand and had a GAAP net loss of $113.16 million

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

CRISPR Therapeutics AG engages in the development and commercialization of therapies derived from genome-editing technology. Its proprietary platform CRISPR/Cas9-based therapeutics allows for precise and directed changes to genomic DNA. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow in 2014 and is headquartered in Zug, Switzerland.

Read More on CRSP:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos